3,3-dimethyl-1-(phenylmethyl)-2,6-piperidinedione | 96326-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3,3-dimethyl-1-(phenylmethyl)-2,6-piperidinedione
• 英文别名: 1-benzyl-3,3-dimethyl-2,6-piperidinedione；1-benzyl-3,3-dimethylpiperidine-2,6-dione；1-benzyl-3,3-dimethylpiperidin-2,5-dione；1-benzyl-3,3-dimethylglutarimide
• CAS: 96326-44-2
• 化学式: C₁₄H₁₇NO₂
• 分子量: 231.294
• InChiKey: CDGJPYJBPLGKOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,3-dimethyl-1-(phenylmethyl)-2,6-piperidinedione 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 24.0h， 生成 3,3-二甲基哌啶
  参考文献：
  名称：

  A multireceptorial binding reinvestigation on an extended class of σ ligands: N-[ω-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards σ1 and EBP sites

  摘要：

  New 1-[omega-(2,3-dihydro-1H-inden-1-yl)- and (2,3-dihydro-5-methoxy-1H-inden-1-yl)alkyl and 1-[omega-(1,2,3,4-tetrahydronaphthalen-1-yl)- and (6-methoxy- or 6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)aIkyl] derivatives of 3,3-dimethylpiperidine were synthesized, as homologous compounds of an existing series of sigma ligands, in order to carry out sigma receptor subtypes structure-affinity relationships. The new compounds and some of their related analogues, already reported, were tested in new multi-receptorial radioligand binding assays. As reference compounds, the known sigma (1) ligands SA 4503, ED 1008 and NE 100 were also prepared and tested. All reported compounds showed high sigma (1) affinity assayed by (+)-[H-3]-pentazocine on guinea-pig brain (apparent K-i = 1.75-72.2 nM) and moderate or low sigma (2) affinity by [H-3]-DTG on rat liver, in contrast with previous results. One tertiary amine function spaced by a five-membered chain from a phenyl group is the structural feature shared by the most active compounds 26 and 43 and some reference al ligands. The reported ol ligands, including reference compounds, also demonstrated a high affinity towards EBP (Delta (8)-Delta (7) sterol isomerase) site (apparent K-i = 0.48-14.8 nM) and some of them (37 and 44) were good ligands at L-type Ca++ channel. 1-14-(2,3-Dihydro- 1H-inden-1-yl)butyl]-3,3-dimethylpiperidine (26) was the best mixed sigma (1) and EBP ligand (apparent K-i = 1.75 and 1.54 nM, respectively) with a good selectivity versus sigma (2) receptor (138- and 157-fold, respectively). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00011-6
• 作为产物：
  描述：

  2,2-二甲基戊二酸 在 氯化亚砜 作用下， 以 乙二醇二甲醚 为溶剂， 反应 28.0h， 生成 3,3-dimethyl-1-(phenylmethyl)-2,6-piperidinedione
  参考文献：
  名称：

  A multireceptorial binding reinvestigation on an extended class of σ ligands: N-[ω-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards σ1 and EBP sites

  摘要：

  New 1-[omega-(2,3-dihydro-1H-inden-1-yl)- and (2,3-dihydro-5-methoxy-1H-inden-1-yl)alkyl and 1-[omega-(1,2,3,4-tetrahydronaphthalen-1-yl)- and (6-methoxy- or 6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)aIkyl] derivatives of 3,3-dimethylpiperidine were synthesized, as homologous compounds of an existing series of sigma ligands, in order to carry out sigma receptor subtypes structure-affinity relationships. The new compounds and some of their related analogues, already reported, were tested in new multi-receptorial radioligand binding assays. As reference compounds, the known sigma (1) ligands SA 4503, ED 1008 and NE 100 were also prepared and tested. All reported compounds showed high sigma (1) affinity assayed by (+)-[H-3]-pentazocine on guinea-pig brain (apparent K-i = 1.75-72.2 nM) and moderate or low sigma (2) affinity by [H-3]-DTG on rat liver, in contrast with previous results. One tertiary amine function spaced by a five-membered chain from a phenyl group is the structural feature shared by the most active compounds 26 and 43 and some reference al ligands. The reported ol ligands, including reference compounds, also demonstrated a high affinity towards EBP (Delta (8)-Delta (7) sterol isomerase) site (apparent K-i = 0.48-14.8 nM) and some of them (37 and 44) were good ligands at L-type Ca++ channel. 1-14-(2,3-Dihydro- 1H-inden-1-yl)butyl]-3,3-dimethylpiperidine (26) was the best mixed sigma (1) and EBP ligand (apparent K-i = 1.75 and 1.54 nM, respectively) with a good selectivity versus sigma (2) receptor (138- and 157-fold, respectively). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00011-6

文献信息

• Asymmetric synthesis catalyzed by chiral ferrocenylphosphine transition metal complexes. 10 gold(i)-catalyzed asymmetric aldol reaction of isocyanoacetate
  作者：Tamio Hayashi、Masaya Sawamura、Yoshihiko Ito

  DOI：10.1016/s0040-4020(01)88870-0

  日期：1992.1

  Optically active ferrocenylbisphosphine ligands containing 2-(dialkylamino)ethylamino group on the ferrocenylmethyl position have been prepared and used for the gold(I)-catalyzed asymmetric aldol reaction of isocyanoacetate with aldehydes. Six-membered ring amines, such as morpholino or piperidino group, at the terminal of the side chain were most stereoselective to give optically active trans-4-

  制备了在二茂铁基甲基位置上含有2-（二烷基氨基）乙基氨基的旋光二茂铁基双膦配体，并将其用于金（I）催化的异氰基乙酸酯与醛的不对称醛醇缩合反应。侧链末端的六元环胺（例如吗啉代或哌啶子基）具有最高的立体选择性，可生成具有高对映体的光学活性反式-4-甲氧羰基-5-烷基-2-恶唑啉（ee最高可达97％） -和非对映选择性的定量收率。
• Chemoselective Hydrogenation of Imides Catalyzed by Cp*Ru(PN) Complexes and Its Application to the Asymmetric Synthesis of Paroxetine
  作者：Masato Ito、Ayaka Sakaguchi、Chika Kobayashi、Takao Ikariya

  DOI：10.1021/ja067777y

  日期：2007.1.1

  This work represents the first catalytic hydrogenation of imides into amides and primary alcohols, in which the unique chemoselectivity is originated from the bifunctional nature of ruthenium-NH moiety in the catalyst.

  这项工作代表了第一次将酰亚胺催化氢化成酰胺和伯醇，其中独特的化学选择性源于催化剂中钌-NH 部分的双功能性质。
• 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders
  申请人：Hodgson Simon Teanby

  公开号：US20080312280A1

  公开（公告）日：2008-12-18

  The present invention relates to a compound of formula (I), or a salt thereof wherein the naphthalene ring is substituted in the 2, 3, 4, 5, 6, 7 or 8 position by R 1 , and R 1 represents —CH 2 CH 2 COOH or —CH═C(CH 3 )COOH, and to processes for their preparation, to compositions containing them and to their use in the treatment of various inflammatory and/or allergic diseases, such as diseases such as allergic rhinitis.

  本发明涉及一种式（I）的化合物或其盐，其中萘环在2、3、4、5、6、7或8位被R1取代，R1代表—CH2CH2COOH或—CH═C(CH3)COOH，以及它们的制备方法、含有它们的组合物以及它们在治疗各种炎症和/或过敏性疾病（如过敏性鼻炎等疾病）中的用途。
• 3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy} phenyl)-1-piperidinyl] carbonyl}-1-naphthalenyl) propanoic or propenoic acid as H1 and H3 receptor antagonists for the treatment of inflammatory and/or allergic disorders
  申请人：Glaxo Group Limited

  公开号：US07989629B2

  公开（公告）日：2011-08-02

  The present invention relates to a compound of formula (I), or a salt thereof wherein the naphthalene ring is substituted in the 2, 3, 4, 5, 6, 7 or 8 position by R1, and R1 represents —CH2CH2COOH or —CH═C(CH3)COOH, and to processes for their preparation, to compositions containing them and to their use in the treatment of various inflammatory and/or allergic diseases, such as diseases such as allergic rhinitis.

  本发明涉及公式（I）的化合物或其盐，其中萘环在2、3、4、5、6、7或8位被R1取代，R1代表—CH2CH2COOH或—CH═C（CH3）COOH，并涉及它们的制备过程、含有它们的组合物以及它们在治疗各种炎症和/或过敏性疾病，如过敏性鼻炎等疾病中的应用。
• 3-(4-{[4-(4-{[3-(3,3-DIMETHYL-1-PIPERIDINYL)PROPYL]OXY}PHENYL)-1-PIPERIDINYL]CARBONYL}-1-NAPHTHALENYL)PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS
  申请人：GLAXO GROUP LIMITED

  公开号：EP2157087A1

  公开（公告）日：2010-02-24

  The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof wherein the naphthalene ring can be substituted in the 2, 3, 4, 5, 6, 7 or 8 position by R1, and R1 represents -CH2CH2COOH or -CH=C(CH3)COOH, in the treatment of various diseases such as nephritis, skin diseases or hypersensitivity reactions.

  本发明涉及式（I）化合物或其药学上可接受的盐的用途 其中萘环可在 2、3、4、5、6、7 或 8 位被 R1 取代，且 R1 代表 -CH2CH2COOH 或 -CH=C(CH3)COOH，用于治疗各种疾病，如肾炎、皮肤病或超敏反应。